2-(4-甲基-3-氧代-3,4-二氢喹喔啉-2-基)肼-1-羧酸乙酯 | 80708-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-(4-甲基-3-氧代-3,4-二氢喹喔啉-2-基)肼-1-羧酸乙酯
• 英文名称: ethyl 2-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)hydrazine-1-carboxylate
• 英文别名: N'-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-hydrazinecarboxylic acid ethyl ester；Ethyl-3-(1-methyl-2-oxo(2H)quinoxalin-3-yl)carbazate；ethyl N-[(4-methyl-3-oxoquinoxalin-2-yl)amino]carbamate
• CAS: 80708-29-8
• 化学式: C₁₂H₁₄N₄O₃
• 分子量: 262.268
• InChiKey: OCAXEKXXQQJRAG-UHFFFAOYSA-N

物化性质

• 熔点：
  200-202 °C
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-甲基-3-氧代-3,4-二氢喹喔啉-2-基)肼-1-羧酸乙酯 在 吡啶 作用下， 以 various solvent(s) 为溶剂， 反应 3.42h， 生成 Methyl 5-methyl-1,4-dioxo-[1,2,4]triazolo[4,3-a]quinoxaline-2-carboxylate
  参考文献：
  名称：

  1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents

  摘要：

  A series of new 1,4-dihydro-1,2,4-triazolo[4,3-]quinoxaline-1,4-diones has been prepared. These compounds were tested as inhibitors of antigen-induced release of histamine (AIR) in vitro from rat peritoneal mast cells (RMC) and as inhibitors of IgE-mediated rat passive cutaneous anaphylaxis (PCA). Most of this new class of antiallergic agents showed good activity in the RMC and PCA tests. The most potent compound, 2-acetyl-7-chloro-5-n-propyl-1,2,4-triazolo[4,3-a]quinoxaline-1,4-dione (1x), with an I50 value of 0.1 microM, is 30 times more potent than disodium cromoglycate (DSCG) in the RMC assay.

  DOI：

  10.1021/jm00381a016
• 作为产物：
  描述：

  N-甲基-1,2-苯二胺 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 5.0h， 生成 2-(4-甲基-3-氧代-3,4-二氢喹喔啉-2-基)肼-1-羧酸乙酯
  参考文献：
  名称：

  1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents

  摘要：

  A series of new 1,4-dihydro-1,2,4-triazolo[4,3-]quinoxaline-1,4-diones has been prepared. These compounds were tested as inhibitors of antigen-induced release of histamine (AIR) in vitro from rat peritoneal mast cells (RMC) and as inhibitors of IgE-mediated rat passive cutaneous anaphylaxis (PCA). Most of this new class of antiallergic agents showed good activity in the RMC and PCA tests. The most potent compound, 2-acetyl-7-chloro-5-n-propyl-1,2,4-triazolo[4,3-a]quinoxaline-1,4-dione (1x), with an I50 value of 0.1 microM, is 30 times more potent than disodium cromoglycate (DSCG) in the RMC assay.

  DOI：

  10.1021/jm00381a016

文献信息

• Thiazoloquinoxalin-1,4-diones for treating allergy
  申请人：USV Pharmaceutical Corporation

  公开号：US04400382A1

  公开（公告）日：1983-08-23

  New triazoloquinoxalin-1,4-diones are described as well as the use thereof as anti-allergenic agents.

  本文介绍了新的三唑并四氧化喹啉-1,4-二酮化合物，并阐述了其作为抗过敏剂的用途。
• Triazoloquinoxalin-1,4-diones
  申请人：USV Pharmaceutical Corporation

  公开号：US04668678A1

  公开（公告）日：1987-05-26

  New triazoloquinoxalin-1,4-diones are described as well as the use thereof as anti-allergenic agents.

  本文描述了新的三唑并喹啉-1,4-二酮化合物，并说明其作为抗过敏药物的用途。
• Pyridotriazolopyrazine-diones for treating allergy
  申请人：USV Pharmaceutical Corporation

  公开号：US04507300A1

  公开（公告）日：1985-03-26

  New triazoloquinoxalin-1,4-diones are described as well as the use thereof as anti-allergenic agents.

  本文描述了新的三唑并喹啉-1,4-二酮化合物，并介绍了它们作为抗过敏剂的用途。
• Photoredox-catalysed chlorination of quinoxalin-2(1<i>H</i>)-ones enabled by using CHCl₃ as a chlorine source
  作者：Mei-Chun Wu、Ming-Zhi Li、Jia-Yi Chen、Jun-An Xiao、Hao-Yue Xiang、Kai Chen、Hua Yang

  DOI：10.1039/d2cc04520f

  日期：——

  photoredox-catalysed chlorination of quinoxalin-2(1H)-ones was developed by using CHCl3 as a chlorine source, thus affording various 3-chloroquinoxalin-2(1H)-ones in moderate to high yields. This protocol is characterized by mild reaction conditions, excellent regioselectivity, and readily available chlorination agent. Considering the operational simplicity and low cost of this chlorination approach, this

  使用 CHCl 3作为氯源，开发了一种光氧化还原催化的 quinoxalin-2(1 H )-ones 氯化反应，从而以中等至高产率提供了各种 3-chloroquinoxalin-2(1 H )-ones。该方案的特点是反应条件温和、区域选择性好、氯化剂易得。考虑到这种氯化方法的操作简单性和低成本，这种开发的方法为将氯官能团快速结合到杂芳烃中提供了一种创新途径，并将激发更广泛地开发新的氯化策略。
• Triazaloquinoxalin-1,4-diones
  申请人：USV PHARMACEUTICAL CORPORATION

  公开号：EP0039920B1

  公开（公告）日：1984-07-25